Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Pharmacokinetics of Droloxifene and Its Metabolites in Breast Cancer Patients

Grill, H. J., Ph.D.; Pollow, K., M.D.

American Journal of Clinical Oncology: 1991 - Volume 14 - Issue - p 21–29
ORIGINAL ARTICLE: PDF Only
Buy

Pharmacokinetics and metabolism of droloxifene, a new antiestrogenic drug, have been investigated by single- and multiple-dose studies in postmenopausal patients with advanced breast cancer. Short terminal elimination half-life, low accumulation, and improved drug tolerability are the most striking features of this safe and effective new antiestrogen. Bioequivalence of film-coated tablet, tablet, and standard solution of droloxifene has been shown. The concentrations of droloxifene and its metabolites have been determined by a highly selective HPLC method.

From the Abteilung für Experimentelle Endokrinologie, Klinikum der Johannes Gutenberg Universität, Mainz, Germany.

© Lippincott-Raven Publishers.